{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:27Z","timestamp":1740107427835,"version":"3.37.3"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s00393-021-01153-6","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T17:02:39Z","timestamp":1643043759000},"page":"286-299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Eosinophile Granulomatose mit Polyangiitis","Eosinophilic granulomatosis with polyangiitis"],"prefix":"10.1007","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8014-1801","authenticated-orcid":false,"given":"Bernhard","family":"Hellmich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1086-1034","authenticated-orcid":false,"given":"Julia","family":"Holle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-9844","authenticated-orcid":false,"given":"Frank","family":"Moosig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"key":"1153_CR1","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.18553\/jmcp.2021.21002","volume":"27","author":"CF Bell","year":"2021","unstructured":"Bell\u00a0CF, Blauer-Peterson\u00a0C, Mao\u00a0J (2021) Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a\u00a0managed care database in the United States. J\u00a0Manag Care Spec Pharm 27:1249\u20131259. https:\/\/doi.org\/10.18553\/jmcp.2021.21002","journal-title":"J Manag Care Spec Pharm"},{"key":"1153_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41943","author":"A Bettiol","year":"2021","unstructured":"Bettiol\u00a0A, Urban\u00a0ML, Dagna\u00a0L et\u00a0al (2021) Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a\u00a0European multicenter observational study. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41943","journal-title":"Arthritis Rheumatol"},{"key":"1153_CR3","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1002\/art.41534","volume":"73","author":"A Canzian","year":"2021","unstructured":"Canzian\u00a0A, Venhoff\u00a0N, Urban\u00a0ML et\u00a0al (2021) Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a\u00a0European collaborative study. Arthritis Rheumatol 73:498\u2013503. https:\/\/doi.org\/10.1002\/art.41534","journal-title":"Arthritis Rheumatol"},{"key":"1153_CR4","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung\u00a0SA, Langford\u00a0CA, Maz\u00a0M et al (2021) 2021 American college of rheumatology\/vasculitis foundation guideline for the management of antineutrophil cytoplasmic antibody-associated Vasculitis. Arthritis Rheumatol 73:1366\u20131383. https:\/\/doi.org\/10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"1153_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1378\/chest.108.2.320","volume":"108","author":"A Churg","year":"1995","unstructured":"Churg\u00a0A, Brallas\u00a0M, Cronin\u00a0SR et al (1995) Formes frustes of Churg-Strauss syndrome. Chest 108:320\u2013323. https:\/\/doi.org\/10.1378\/chest.108.2.320","journal-title":"Chest"},{"key":"1153_CR6","first-page":"277","volume":"27","author":"J Churg","year":"1951","unstructured":"Churg\u00a0J, Strauss\u00a0L (1951) Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 27:277\u2013301","journal-title":"Am J Pathol"},{"key":"1153_CR7","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1001\/jama.1936.02770450039010","volume":"107","author":"MB Cohen","year":"1936","unstructured":"Cohen\u00a0MB, Kline\u00a0BS, Young\u00a0AM (1936) The clinical diagnosis of periarteriitis nodosa. JAMA 107:1555\u20131558","journal-title":"JAMA"},{"key":"1153_CR8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.22679","volume":"57","author":"P Cohen","year":"2007","unstructured":"Cohen\u00a0P, Pagnoux\u00a0C, Mahr\u00a0A et al (2007) Churg-Strauss syndrome with poor-prognosis factors: a prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 57:686\u2013693. https:\/\/doi.org\/10.1002\/art.22679","journal-title":"Arthritis Rheum"},{"key":"1153_CR9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/art.37721","volume":"65","author":"C Comarmond","year":"2013","unstructured":"Comarmond\u00a0C, Pagnoux\u00a0C, Khellaf\u00a0M et al (2013) Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383\u00a0patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum 65:270\u2013281. https:\/\/doi.org\/10.1002\/art.37721","journal-title":"Arthritis Rheum"},{"key":"1153_CR10","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","volume":"77","author":"G Emmi","year":"2018","unstructured":"Emmi\u00a0G, Rossi\u00a0GM, Urban\u00a0ML et\u00a0al (2018) Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 77:952\u2013954. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211897","journal-title":"Ann Rheum Dis"},{"key":"1153_CR11","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/art.1780381116","volume":"38","author":"L Guillevin","year":"1995","unstructured":"Guillevin\u00a0L, Lhote\u00a0F, Cohen\u00a0F et al (1995) Corticosteroids plus pulse cyclophosphamide and plasma exchanges versus corticosteroids plus pulse cyclophosphamide alone in the treatment of polyarteriitis nodosa and Chrug-Strauss syndrome patients with factors predicting poor prognosis. A prospective, randomized trial in sixty-two patients. Arthritis Rheum 38:1638\u20131645","journal-title":"Arthritis Rheum"},{"key":"1153_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/MD.0b013e318205a4c6","volume":"90","author":"L Guillevin","year":"2011","unstructured":"Guillevin\u00a0L, Pagnoux\u00a0C, Seror\u00a0R et al (2011) The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort. Medicine 90:19\u201327. https:\/\/doi.org\/10.1097\/MD.0b013e318205a4c6","journal-title":"Medicine"},{"key":"1153_CR13","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","volume":"9","author":"VP Guntur","year":"2021","unstructured":"Guntur\u00a0VP, Manka\u00a0LA, Denson\u00a0JL et al (2021) Benralizumab as a\u00a0steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. J\u00a0Allergy Clin Immunol Pract 9:1186\u20131193.e1. https:\/\/doi.org\/10.1016\/j.jaip.2020.09.054","journal-title":"J Allergy Clin Immunol Pract"},{"key":"1153_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/archinte.1941.00200040002001","volume":"67","author":"J Harkavy","year":"1941","unstructured":"Harkavy\u00a0J (1941) Vascular Allergy. Pathogenesis of bronchial asthma with recurrent pulmonary infiltrations and eoinophilic polyserositis. Arch Intern Med 67:709","journal-title":"Arch Intern Med"},{"key":"1153_CR15","first-page":"S69","volume":"21","author":"B Hellmich","year":"2003","unstructured":"Hellmich\u00a0B, Ehlers\u00a0S, Csernok\u00a0E et al (2003) Update on the pathogenesis of Churg-Strauss syndrome. Clin Exp Rheumatol 21:S69\u2013S77","journal-title":"Clin Exp Rheumatol"},{"key":"1153_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1517\/14656566.5.1.25","volume":"5","author":"B Hellmich","year":"2004","unstructured":"Hellmich\u00a0B, Gross\u00a0WL (2004) Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 5:25\u201335. https:\/\/doi.org\/10.1517\/14656566.5.1.25","journal-title":"Expert Opin Pharmacother"},{"key":"1153_CR17","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1007\/s00108-007-2009-4","volume":"49","author":"B Hellmich","year":"2008","unstructured":"Hellmich\u00a0B, Holl-Ulrich\u00a0K, Merz\u00a0H et al (2008) Hypereosinophilic syndrome and Churg-Strauss syndrome: is it clinically relevant to differentiate these syndromes? Internist 49:286\u2013296. https:\/\/doi.org\/10.1007\/s00108-007-2009-4","journal-title":"Internist"},{"key":"1153_CR18","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1093\/rheumatology\/keaa924","volume":"60","author":"B Hellmich","year":"2021","unstructured":"Hellmich\u00a0B, Lamprecht\u00a0P, Spearpoint\u00a0P et al (2021) New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a\u00a0claims data study. Rheumatology 60:4868\u20134873. https:\/\/doi.org\/10.1093\/rheumatology\/keaa924","journal-title":"Rheumatology"},{"key":"1153_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00393-018-0587-2","volume":"78","author":"JC Henes","year":"2019","unstructured":"Henes\u00a0JC, Wirths\u00a0S, Hellmich\u00a0B (2019) Differentialdiagnosis der Hypereosinophiliie. Z\u00a0Rheumatol 78:313\u2013321. https:\/\/doi.org\/10.1007\/s00393-018-0587-2","journal-title":"Z Rheumatol"},{"key":"1153_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab495","author":"M Iudici","year":"2021","unstructured":"Iudici\u00a0M, Puechal\u00a0X, Pagnoux\u00a0C et\u00a0al (2021) Significance of eosinophilia in granulomatosis with polyangiitis: data from the French Vasculitis Study Group Registry. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab495","journal-title":"Rheumatology"},{"key":"1153_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-021-05783-8","author":"RW Jakes","year":"2021","unstructured":"Jakes\u00a0RW, Kwon\u00a0N, Nordstrom\u00a0B et al (2021) Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a\u00a0systematic literature review and meta-analysis. Clin Rheumatol. https:\/\/doi.org\/10.1007\/s10067-021-05783-8","journal-title":"Clin Rheumatol"},{"key":"1153_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC, Falk\u00a0RJ, Bacon\u00a0PA et\u00a0al (2013) 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 65:1\u201311. https:\/\/doi.org\/10.1002\/art.37715","journal-title":"Arthritis Rheum"},{"key":"1153_CR23","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","volume":"125","author":"S Kim","year":"2010","unstructured":"Kim\u00a0S, Marigowda\u00a0G, Oren\u00a0E et al (2010) Mepolizumab as a\u00a0steroid-sparing treatment option in patients with Churg-Strauss syndrome. J\u00a0Allergy Clin Immunol 125:1336\u20131343. https:\/\/doi.org\/10.1016\/j.jaci.2010.03.028","journal-title":"J Allergy Clin Immunol"},{"key":"1153_CR24","first-page":"484","volume":"1","author":"A Kussmaul","year":"1866","unstructured":"Kussmaul\u00a0A, Maier\u00a0R (1866) Ueber eine bisher nicht beschriebene eigent\u00fcmliche Arterienerkrankung (Periarteritis nodosa), die mit Morbus Bright\u00fc und rapid fortschreitender allgemeiner Muskell\u00e4hmung einhergeht. Dtsch Arch Klin Med 1:484\u2013518","journal-title":"Dtsch Arch Klin Med"},{"key":"1153_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/00005792-198403000-00001","volume":"63","author":"JG Lanham","year":"1984","unstructured":"Lanham\u00a0JG, Elkon\u00a0KB, Pusey\u00a0CD et al (1984) Systemic vasculitis with asthma and eosinophilia: a\u00a0clinical approach to the Churg-Strauss syndrome. Medicine 63:65\u201381. https:\/\/doi.org\/10.1097\/00005792-198403000-00001","journal-title":"Medicine"},{"issue":"Suppl 129","key":"1153_CR26","doi-asserted-by":"publisher","first-page":"83","DOI":"10.55563\/clinexprheumatol\/08k9af","volume":"39","author":"K Laskari","year":"2021","unstructured":"Laskari\u00a0K, Hellmich\u00a0B, Adamus\u00a0G et al (2021) Autoantibody profile in eosinophilic granulomatosis and polyangiitis: predominance of anti-alpha-enolase antibodies. Clin Exp Rheumatol 39(Suppl 129):83\u201387","journal-title":"Clin Exp Rheumatol"},{"key":"1153_CR27","unstructured":"Grayson P et al (2022) ACR\/EULAR classification criteria for ANCA-associated vasculitis. Arthritis Rheumatol. (in press)"},{"key":"1153_CR28","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1038\/s41467-019-12515-9","volume":"10","author":"PA Lyons","year":"2019","unstructured":"Lyons\u00a0PA, Peters\u00a0JE, Alberici\u00a0F et al (2019) Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status. Nat Commun 10:5120. https:\/\/doi.org\/10.1038\/s41467-019-12515-9","journal-title":"Nat Commun"},{"key":"1153_CR29","doi-asserted-by":"publisher","first-page":"kez057.026","DOI":"10.1093\/rheumatology\/kez057.026","volume":"58","author":"J Mahrhold","year":"2019","unstructured":"Mahrhold\u00a0J, Hellmich\u00a0B, Csernok\u00a0E (2019) Anca status in eosinophil granulomatosis with polyangiitis: a monocentric cohort analysis of manifestations and relapses of anca-positive and anca-negative patients. Rheumatology 58:kez057.026. https:\/\/doi.org\/10.1093\/rheumatology\/kez057.026","journal-title":"Rheumatology"},{"key":"1153_CR30","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.anai.2021.01.035","volume":"126","author":"LA Manka","year":"2021","unstructured":"Manka\u00a0LA, Guntur\u00a0VP, Denson\u00a0JL et\u00a0al (2021) Efficacy and safety of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. Ann Allergy Asthma Immunol 126:696\u2013701.e1. https:\/\/doi.org\/10.1016\/j.anai.2021.01.035","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1153_CR31","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/art.1780330806","volume":"33","author":"AT Masi","year":"1990","unstructured":"Masi\u00a0AT, Hunder\u00a0GG, Lie\u00a0JT et al (1990) The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 33:1094\u20131100. https:\/\/doi.org\/10.1002\/art.1780330806","journal-title":"Arthritis Rheum"},{"key":"1153_CR32","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1093\/rheumatology\/keab046","volume":"60","author":"VG Menditto","year":"2021","unstructured":"Menditto\u00a0VG, Rossetti\u00a0G, Olivari\u00a0D et\u00a0al (2021) Rituximab for eosinophilic granulomatosis with polyangiitis: a\u00a0systematic review of observational studies. Rheumatology 60:1640\u20131650. https:\/\/doi.org\/10.1093\/rheumatology\/keab046","journal-title":"Rheumatology"},{"key":"1153_CR33","first-page":"24","volume":"28","author":"C Metzler","year":"2010","unstructured":"Metzler\u00a0C, Csernok\u00a0E, Gross\u00a0WL et al (2010) Interferon-alpha for maintenance of remission in Churg-Strauss syndrome: a\u00a0long-term observational study. Clin Exp Rheumatol 28:24\u201330","journal-title":"Clin Exp Rheumatol"},{"key":"1153_CR34","first-page":"S52","volume":"22","author":"C Metzler","year":"2004","unstructured":"Metzler\u00a0C, Hellmich\u00a0B, Gause\u00a0A et\u00a0al (2004) Churg Strauss syndrome\u2014successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 22:S52\u2013S61","journal-title":"Clin Exp Rheumatol"},{"key":"1153_CR35","first-page":"S35","volume":"26","author":"C Metzler","year":"2008","unstructured":"Metzler\u00a0C, Schnabel\u00a0A, Gross\u00a0WL et al (2008) A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 26:S35\u2013S40","journal-title":"Clin Exp Rheumatol"},{"key":"1153_CR36","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","volume":"75","author":"AJ Mohammad","year":"2016","unstructured":"Mohammad\u00a0AJ, Hot\u00a0A, Arndt\u00a0F et al (2016) Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Ann Rheum Dis 75:396\u2013401. https:\/\/doi.org\/10.1136\/annrheumdis-2014-206095","journal-title":"Ann Rheum Dis"},{"key":"1153_CR37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202005-1628SO","author":"S Moiseev","year":"2020","unstructured":"Moiseev\u00a0S, Bossuyt\u00a0X, Arimura\u00a0Y et\u00a0al (2020) International consensus on ANCA testing in eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med. https:\/\/doi.org\/10.1164\/rccm.202005-1628SO","journal-title":"Am J Respir Crit Care Med"},{"key":"1153_CR38","doi-asserted-by":"publisher","first-page":"102618","DOI":"10.1016\/j.autrev.2020.102618","volume":"19","author":"S Moiseev","year":"2020","unstructured":"Moiseev\u00a0S, Cohen Tervaert\u00a0JW, Arimura\u00a0Y et\u00a0al (2020) 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 19:102618. https:\/\/doi.org\/10.1016\/j.autrev.2020.102618","journal-title":"Autoimmun Rev"},{"key":"1153_CR39","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","volume":"72","author":"F Moosig","year":"2013","unstructured":"Moosig\u00a0F, Bremer\u00a0JP, Hellmich\u00a0B et al (2013) A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150\u00a0patients. Ann Rheum Dis 72:1011\u20131017. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201531","journal-title":"Ann Rheum Dis"},{"key":"1153_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","volume":"155","author":"F Moosig","year":"2011","unstructured":"Moosig\u00a0F, Gross\u00a0WL, Herrmann\u00a0K et al (2011) Targeting interleukin\u20115 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 155:341\u2013343. https:\/\/doi.org\/10.7326\/0003-4819-155-5-201109060-00026","journal-title":"Ann Intern Med"},{"key":"1153_CR41","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1164\/rccm.201804-0809OC","volume":"199","author":"M Mukherjee","year":"2019","unstructured":"Mukherjee\u00a0M, Thomas\u00a0SR, Radford\u00a0K et al (2019) Sputum antineutrophil cytoplasmic antibodies in serum antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med 199:158\u2013170. https:\/\/doi.org\/10.1164\/rccm.201804-0809OC","journal-title":"Am J Respir Crit Care Med"},{"key":"1153_CR42","doi-asserted-by":"publisher","first-page":"102725","DOI":"10.1016\/j.jaut.2021.102725","volume":"124","author":"R Padoan","year":"2021","unstructured":"Padoan\u00a0R, Gatto\u00a0M, Ghirardello\u00a0A et al (2021) IgG anti-Pentraxin 3 antibodies are a\u00a0novel biomarker of ANCA-associated vasculitis and better identify patients with eosinophilic granulomatosis with polyangiitis. J\u00a0Autoimmun 124:102725. https:\/\/doi.org\/10.1016\/j.jaut.2021.102725","journal-title":"J Autoimmun"},{"key":"1153_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/art.39011","volume":"67","author":"C Pagnoux","year":"2015","unstructured":"Pagnoux\u00a0C, Quemeneur\u00a0T, Ninet\u00a0J et al (2015) Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a\u00a0multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol 67:1117\u20131127. https:\/\/doi.org\/10.1002\/art.39011","journal-title":"Arthritis Rheumatol"},{"key":"1153_CR44","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.1093\/rheumatology\/keaa805","volume":"60","author":"M Papo","year":"2021","unstructured":"Papo\u00a0M, Sinico\u00a0RA, Teixeira\u00a0V et al (2021) Significance of PR3-ANCA positivity in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology 60:4355\u20134360. https:\/\/doi.org\/10.1093\/rheumatology\/keaa805","journal-title":"Rheumatology"},{"key":"1153_CR45","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1007\/s00296-021-04961-w","volume":"41","author":"M Philobos","year":"2021","unstructured":"Philobos\u00a0M, Perkins\u00a0A, Karabayas\u00a0M et al (2021) A real-world assessment of mycophenolate mofetil for remission induction in eosinophilic granulomatosis with polyangiitis. Rheumatol Int 41:1811\u20131814. https:\/\/doi.org\/10.1007\/s00296-021-04961-w","journal-title":"Rheumatol Int"},{"key":"1153_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2021.05.014","author":"IJ Pouliquen","year":"2021","unstructured":"Pouliquen\u00a0IJ, Austin\u00a0D, Steinfeld\u00a0J et\u00a0al (2021) Justification of the subcutaneous mepolizumab dose of 300\u202fmg in eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Clin Ther. https:\/\/doi.org\/10.1016\/j.clinthera.2021.05.014","journal-title":"Clin Ther"},{"key":"1153_CR47","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/rheumatology\/kez139","volume":"58","author":"X Puechal","year":"2019","unstructured":"Puechal\u00a0X, Pagnoux\u00a0C, Baron\u00a0G et al (2019) Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. Rheumatology 58:2107\u20132116. https:\/\/doi.org\/10.1093\/rheumatology\/kez139","journal-title":"Rheumatology"},{"key":"1153_CR48","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1002\/art.40205","volume":"69","author":"X Puechal","year":"2017","unstructured":"Puechal\u00a0X, Pagnoux\u00a0C, Baron\u00a0G et al (2017) Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial. Arthritis Rheumatol 69:2175\u20132186. https:\/\/doi.org\/10.1002\/art.40205","journal-title":"Arthritis Rheumatol"},{"key":"1153_CR49","first-page":"112","volume":"54","author":"FM Rackemann","year":"1939","unstructured":"Rackemann\u00a0FM, Greene\u00a0JE (1939) Periarteritis nodosa and asthma. Am Physiicians 54:112\u2013118","journal-title":"Am Physiicians"},{"key":"1153_CR50","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/art.23198","volume":"58","author":"C Ribi","year":"2008","unstructured":"Ribi\u00a0C, Cohen\u00a0P, Pagnoux\u00a0C et al (2008) Treatment of Churg-Strauss syndrome without poor-prognosis factors: a\u00a0multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 58:586\u2013594. https:\/\/doi.org\/10.1002\/art.23198","journal-title":"Arthritis Rheum"},{"key":"1153_CR51","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.autrev.2014.08.002","volume":"13","author":"M Samson","year":"2014","unstructured":"Samson\u00a0M, Puechal\u00a0X, Devilliers\u00a0H et al (2014) Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmun Rev 13:945\u2013953. https:\/\/doi.org\/10.1016\/j.autrev.2014.08.002","journal-title":"Autoimmun Rev"},{"key":"1153_CR52","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","volume":"43","author":"M Samson","year":"2013","unstructured":"Samson\u00a0M, Puechal\u00a0X, Devilliers\u00a0H et al (2013) Long-term outcomes of 118\u00a0patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials. J\u00a0Autoimmun 43:60\u201369. https:\/\/doi.org\/10.1016\/j.jaut.2013.03.003","journal-title":"J Autoimmun"},{"key":"1153_CR53","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab514","author":"S Sartorelli","year":"2021","unstructured":"Sartorelli\u00a0S, Chassagnon\u00a0G, Cohen\u00a0P et al (2021) Revisiting characteristics, treatment and outcome of cardiomyopathy in eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab514","journal-title":"Rheumatology"},{"key":"1153_CR54","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00393-017-0394-1","volume":"76","author":"JH Schirmer","year":"2017","unstructured":"Schirmer\u00a0JH, Aries\u00a0PM, De Groot\u00a0K et al (2017) S1 Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden. Z\u00a0Rheumatol 76:77\u2013104. https:\/\/doi.org\/10.1007\/s00393-017-0394-1","journal-title":"Z Rheumatol"},{"key":"1153_CR55","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/art.21250","volume":"52","author":"RA Sinico","year":"2005","unstructured":"Sinico\u00a0RA, Di Toma\u00a0L, Maggiore\u00a0U et al (2005) Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 52:2926\u20132935. https:\/\/doi.org\/10.1002\/art.21250","journal-title":"Arthritis Rheum"},{"key":"1153_CR56","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1002\/acr.23912","volume":"72","author":"R Solans-Laque","year":"2020","unstructured":"Solans-Laque\u00a0R, Rodriguez-Carballeira\u00a0M, Rios-Blanco\u00a0JJ et al (2020) Comparison of the Birmingham vasculitis activity score and the five-factor score to assess survival in antineutrophil cytoplasmic antibody-associated Vasculitis: a study of 550 patients from Spain (REVAS registry). Arthritis Care Res 72:1001\u20131010. https:\/\/doi.org\/10.1002\/acr.23912","journal-title":"Arthritis Care Res"},{"key":"1153_CR57","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/acr2.11230","volume":"3","author":"JM Springer","year":"2021","unstructured":"Springer\u00a0JM, Kalot\u00a0MA, Husainat\u00a0NM et al (2021) Granulomatosis with polyangiitis and microscopic polyangiitis: a systematic review and meta-analysis of benefits and harms of common treatments. ACR Open Rheumatol 3:196\u2013205. https:\/\/doi.org\/10.1002\/acr2.11230","journal-title":"ACR Open Rheumatol"},{"key":"1153_CR58","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1016\/j.jaci.2018.11.041","volume":"143","author":"J Steinfeld","year":"2019","unstructured":"Steinfeld\u00a0J, Bradford\u00a0ES, Brown\u00a0J et\u00a0al (2019) Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. J\u00a0Allergy Clin Immunol 143:2170\u20132177. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.041","journal-title":"J Allergy Clin Immunol"},{"key":"1153_CR59","doi-asserted-by":"publisher","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","volume":"5","author":"V Teixeira","year":"2019","unstructured":"Teixeira\u00a0V, Mohammad\u00a0AJ, Jones\u00a0RB et\u00a0al (2019) Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open 5:e905. https:\/\/doi.org\/10.1136\/rmdopen-2019-000905","journal-title":"RMD Open"},{"key":"1153_CR60","unstructured":"Terrier B, Pugnet G, De Moreuil C et al (2021) Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: a double-blind, randomized, controlled trial [abstract]. Arthritis & rheumatology 73 (suppl 10). https:\/\/acrabstracts.org\/abstract\/rituximab-versus-conventional-therapeutic-strategy-for-remission-induction-in-eosinophilic-granulomatosis-with-polyangiitis-a-double-blind-randomized-controlled-trial\/. Zugegriffen: 27. Okt. 2021"},{"key":"1153_CR61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1136\/ard.2006.054593","volume":"66","author":"R Watts","year":"2007","unstructured":"Watts\u00a0R, Lane\u00a0S, Hanslik\u00a0T et al (2007) Development and validation of a\u00a0consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 66:222\u2013227. https:\/\/doi.org\/10.1136\/ard.2006.054593","journal-title":"Ann Rheum Dis"},{"key":"1153_CR62","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler\u00a0ME, Akuthota\u00a0P, Jayne\u00a0D et\u00a0al (2017) Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N\u00a0Engl J Med 376:1921\u20131932. https:\/\/doi.org\/10.1056\/NEJMoa1702079","journal-title":"N Engl J Med"},{"key":"1153_CR63","first-page":"195","volume":"30","author":"KS Wilson","year":"1945","unstructured":"Wilson\u00a0KS, Alexander\u00a0HL (1945) The relation of periarteritis nodosa to bronchial astham and other forms of hypersensitiveness. J\u00a0Lab Clin Med 30:195\u2013203","journal-title":"J Lab Clin Med"},{"key":"1153_CR64","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","volume":"75","author":"M Yates","year":"2016","unstructured":"Yates\u00a0M, Watts\u00a0RA, Bajema\u00a0IM et al (2016) EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 75:1583\u20131594. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209133","journal-title":"Ann Rheum Dis"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-01153-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01153-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T11:07:44Z","timestamp":1651489664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-01153-6"}},"subtitle":["Update zu Klassifikation und Management","Update on classification and management"],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":64,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1153"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-01153-6","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"type":"print","value":"0340-1855"},{"type":"electronic","value":"1435-1250"}],"subject":[],"published":{"date-parts":[[2022,1,24]]},"assertion":[{"value":"16 December 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Hellmich: Vortragshonorare: Boehringer, GSK, Roche, Vifor. Honorare f\u00fcr Beratungsleistungen: InflaRx, GSK, Roche, Vifor. J.\u00a0Holle und F.\u00a0Moosig geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}